Paradigm Biocapital Advisors LP
CIK: 0001855655Latest portfolio: $3.9B · Q4 2025
Holdings
30
Total Value
$3.9B
New Positions
8
Closed Positions
12
Top Holdings
View All 30 Holdings →| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | NUVLNUVALENT INC | 5,269,433 | $530.1M | 13.53% | — | |
| 2 | RVMDREVOLUTION MEDICINES INC | 6,644,403 | $529.2M | 13.51% | +421K | |
| 3 | ACLXARCELLX INC | 5,724,016 | $373.2M | 9.53% | +1.1M | |
| 4 | GMABGENMAB A/S | 7,039,834 | $216.8M | 5.53% | +3.2M | |
| 5 | TARSTARSUS PHARMACEUTICALS INC | 2,562,154 | $209.8M | 5.35% | -103,544 | |
| 6 | ABVXABIVAX SA | 1,417,473 | $191.2M | 4.88% | -146,723 | |
| 7 | OLMAOLEMA PHARMACEUTICALS INC | 7,544,172 | $188.6M | 4.81% | +750K | |
| 8 | PCVXVAXCYTE INC | 4,068,020 | $187.7M | 4.79% | +283K | |
| 9 | XBISPDR SERIES TRUST | 1,500,000 | $182.9M | 4.67% | +500K | Put |
| 10 | CDTXCIDARA THERAPEUTICS INC | 759,565 | $167.8M | 4.28% | -201,599 | |
| 11 | EWTXEDGEWISE THERAPEUTICS INC | 6,541,210 | $162.3M | 4.14% | +371K | |
| 12 | SRRKSCHOLAR ROCK HLDG CORP | 3,062,157 | $134.9M | 3.44% | +1.1M | |
| 13 | URGNUROGEN PHARMA LTD | 4,473,648 | $104.8M | 2.67% | +258K | |
| 14 | CRNXCRINETICS PHARMACEUTICALS IN | 2,210,774 | $102.9M | 2.63% | -340,000 | |
| 15 | APGEAPOGEE THERAPEUTICS INC | 1,123,243 | $84.8M | 2.16% | -398,514 | |
| 16 | EYPTEYEPOINT INC | 3,691,475 | $67.4M | 1.72% | +1.7M | |
| 17 | ERASERASCA INC | 14,159,095 | $52.7M | 1.34% | +599K | |
| 18 | BBIOBRIDGEBIO PHARMA INC | 684,277 | $52.3M | 1.34% | — | |
| 19 | ORKAORUKA THERAPEUTICS INC | 1,710,316 | $51.8M | 1.32% | NEW | |
| 20 | SYRESPYRE THERAPEUTICS INC | 1,467,266 | $48.1M | 1.23% | — | |
| 21 | LXEOLEXEO THERAPEUTICS INC | 4,763,198 | $47.3M | 1.21% | NEW | |
| 22 | VRDNVIRIDIAN THERAPEUTICS INC | 1,443,102 | $44.9M | 1.15% | -1,166,251 | |
| 23 | OCULOCULAR THERAPEUTIX INC | 2,935,284 | $35.6M | 0.91% | -562,023 | |
| 24 | TERNTERNS PHARMACEUTICALS INC | 810,286 | $32.7M | 0.84% | NEW | |
| 25 | BBOTBRIDGEBIO ONCOLOGY THERAPEUT | 2,261,749 | $28.3M | 0.72% | +396K |
Quarterly Changes
New Positions
Increased Positions
Sector Breakdown
Healthcare0.0% ($5.300525292263732e+141T)
Financial Services0.0% ($182.9M)
Unknown0.0% ($167.8M)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 17, 2026 | $3.9B | 30 |
| Q3 2025 | Nov 14, 2025 | $3.5T | 36 |
| Q2 2025 | Aug 14, 2025 | $2.3T | 28 |
| Q1 2025 | May 15, 2025 | $2.2T | 28 |
| Q4 2024 | Feb 14, 2025 | $2.9T | 28 |
| Q3 2024 | Nov 14, 2024 | $2955.9T | 33 |
| Q2 2024 | Aug 14, 2024 | $2613.0T | 35 |
| Q1 2024 | May 15, 2024 | $2840.8T | 34 |
| Q4 2023 | Feb 14, 2024 | $2135.9T | 30 |
| Q3 2023 | Nov 14, 2023 | $1473.7T | 31 |
| Q2 2023 | Aug 14, 2023 | $1294.2T | 30 |
| Q1 2023 | May 15, 2023 | $1055.2T | 25 |
| Q4 2022 | Feb 14, 2023 | $851.9T | 23 |
| Q3 2022 | Nov 14, 2022 | $750.1B | 28 |
| Q2 2022 | Aug 15, 2022 | $501.5B | 23 |
| Q1 2022 | May 16, 2022 | $378.2B | 25 |
| Q4 2021 | Feb 14, 2022 | $350.2B | 24 |
Fund Information
Paradigm Biocapital Advisors LP is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $3.9B across 30 holdings. The largest position is NUVALENT INC (NUVL), representing 13.5% of the portfolio. Compared to the previous quarter, the fund opened 8 new positions and closed 12 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.